BI1808-hIgG1

BI-1808, an IgG1 monoclonal antibody of human origin, is designed to selectively target TNFR2 by disrupting its interaction with the ligand TNF-α. This action facilitates the FcγR-dependent elimination of intratumoral regulatory T cells (Tregs) while concurrently fostering the proliferation of intratumoral CD8+ T cells. In preclinical studies involving immunocompetent mice bearing tumors and displaying partial sensitivity to checkpoint blockade, the co-administration of BI-1808 with surrogate antibodies mimicking anti-PD-1 resulted in complete remission across all treated mice. This observed outcome suggests a potential synergistic effect between these agents, culminating in the complete cure of the subjects.